Showing results (111-120 of 526) with videos related to
Sort By:
Pageof 53
Drug Safety|March 10, 2001
What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?V Ozdemir, N H Shear, W KalowThe Journal of Urology|November 1, 1992
Quantitative measurements of prostatic blood flow and blood volume by positron emission tomographyT InabaPharmacology & Therapeutics|January 1, 1990
Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylationT InabaCanadian Journal of Physiology and Pharmacology|September 1, 1989
Cocaine: pharmacokinetics and biotransformation in manT InabaClinical Pharmacology and Therapeutics|August 1, 1987
A urinary metabolite ratio that reflects systemic caffeine clearanceM E Campbell, S P Spielberg, W KalowJournal of Chromatography|May 31, 1985
Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disordersT P Kruck, W Kalow, D R McLachlanJournal of Clinical Psychopharmacology|July 31, 2001
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophreniaV Ozdemir, W Kalow, P Posner, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1978
The fate of [7-3H]isoproterenol in cats after intravenous administrationD Kadar, A J Lovrics, L EndrenyiToxicology Letters|September 1, 1992
Inhibition of human hepatic glutathione S-transferase isozymes by ethacrynic acid and its metabolitesY Takamatsu, T InabaAntimicrobial Agents and Chemotherapy|July 14, 1998
Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitorsS Fayz, T InabaPageof 53